Company news
Poolbeg Pharma PLC news in 2024
Poolbeg Pharma PLC's news releases, calls and decks from 2024, newest first.
Poolbeg presents POLB 001 data at 66th ASH Meeting
December 9, 2024
POLB 001 Patent Granted in United States
November 20, 2024
POLB 001 data to be presented at ASH
November 6, 2024
Interim results for the six months to 30 June 2024
September 18, 2024
H.C. Wainwright Global Investment Conference
August 27, 2024
Poolbeg Pharma plc - Voluntary Delisting from OTCQB Market
July 29, 2024
Voluntary Delisting from OTCQB Market
July 26, 2024
Change of Registered Address
July 2, 2024
Result of AGM
June 17, 2024
Poolbeg Pharma plc - Annual Report and AGM Notice
May 10, 2024
Annual Report & AGM Notice
May 9, 2024
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
May 8, 2024
Significant POLB 001 Patent Granted in USA
May 1, 2024
Appointment of Joint Broker
April 30, 2024
Option Agreement to Acquire Orphan Drug Candidate
April 30, 2024
Results for the year ended 31 December 2023
April 30, 2024
TR-1: Notification of major holdings
April 29, 2024
POLB 001 US Patent Update
March 20, 2024
Poolbeg Pharma plc - Director Share Purchase
February 23, 2024
Director Share Purchase
February 19, 2024
Board Role Change and Launch of EIP
February 15, 2024
Market Opportunity for POLB 001 for CRS
February 12, 2024
Poolbeg Pharma plc - Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome
January 18, 2024
Further data shows POLB001 potential in cancer CRS
January 17, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (May 2024)
Investor deck · 38 slides · May 2024